株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオテクノロジーAPI製造サービス:世界の業界と市場

Biotech API Manufacturing Services: World Industry and Market 2014-2024

発行 Visiongain Ltd 商品コード 291303
出版日 ページ情報 英文 173 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=146.92円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオテクノロジーAPI製造サービス:世界の業界と市場 Biotech API Manufacturing Services: World Industry and Market 2014-2024
出版日: 2013年12月12日 ページ情報: 英文 173 Pages
概要

近年哺乳類の細胞培養や微生物の発酵(培養)などを中心とした生物医薬品原薬(API)製造受託サービスの市場が新たな成長市場として脚光を浴びています。世界市場の規模は、2018年の時点で52億2,000万ドルに達し、その後も着実に成長を続けると見られています。

本調査レポートは、生物学的製剤のAPI製造業務を請け負っているCMO(医薬品製造受託機関)の市場に光を当て、2012〜2013年の動向を明らかにするとともに、2014〜2024年までの予測を示したもので、米国や欧州諸国、日本などの先進国のみならず、ブラジル、ロシア、インド、中国、シンガポール、韓国などの新興国市場に関する詳細な分析、主要企業165社のデータや注目企業4社の幹部に対するインタビューなどを盛り込み、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

  • バイオテクノロジーAPI製造受託サービス:2013年の世界市場
  • 本書の内容
  • 調査方法
  • バイオテクノロジーAPI製造の概要

第2章 2014〜2024年の世界市場の展望と予測

  • 2012〜2013年のバイオテクノロジーAPI製造アウトソーシング需要
  • 2014〜2024年のバイオテクノロジーAPI製造アウトソーシング市場
  • 2014〜2024年の哺乳類細胞培養市場
  • 2014〜2024年の微生物発酵市場
  • 本章のサマリー:急成長が見込まれる2012〜2024年の市場

第3章 2014〜2024年の主要国市場

  • 2012〜2013年の市場の中心は米国と欧州
  • 2014〜2024年の欧州市場
    • 急成長が見込まれる欧州の市場
    • 収益予測
    • 主なEU加盟国の市場
    • 欧州市場をリードするドイツ
    • 英国市場
    • フランス市場の予測
    • 研究開発分野をリードするスイス
    • スペイン市場の予測
    • 小分子APIの分野で伝統的な強みを発揮するイタリア
  • 米国:世界最大のバイオテクノロジーAPI製造委託サービス市場
  • 日本:比較的新しい市場
  • 2014〜2024年の新興国市場
    • 2013年の時点では規模の小さい新興国市場
    • 活発化するバイオシミラーと生物学的製剤の開発
    • 中国への投資を進めるCMO
    • インド市場の展望
    • 韓国の2大CMO
    • 今後の投資拡大が見込まれるシンガポール
    • ブラジルおよびロシア政府のバイオテクノロジー開発促進策
  • 本章のサマリー:2014〜2024年の主要国市場の展望

第4章 2014〜2024年の各種生物学的製剤市場の展望

  • 抗体治療薬:最大の規模を有する生物学的製剤市場
    • 2013年のモノクローナル抗体製造業務受託サービス市場
    • 抗体API製造のアウトソーシング
    • CMOにとって新たな課題となっている次世代抗体治療薬
  • インスリン治療薬市場の展望
  • ホルモンAPI製造受託サービス
  • インターフェロン市場
  • ワクチン製造
  • 本章のサマリー:2014〜2024年の主な生物学的製剤製造業務アウトソーシング市場

第5章 2014〜2024年の業界のトレンド

  • 2012〜2013年に明らかになった強みと弱み
  • 2014〜2014年の機会と脅威
  • 社会、技術、経済、政治(STEP)の各要因に関する分析
  • 生物学的製剤開発のトレンド
  • 単回使用技術の展望
  • アウトソーシングのトレンド
  • 新たな製造プラットフォーム
  • 本章のサマリー:2024年までの業界のトレンド

第6章 主なCMOの2013年の動向

  • 4社が市場をリード
  • Boehringer Ingelheim BioXcellence
  • Celltrion:アジア地域に大きな製造能力を保有
  • DSM Biologics
  • Lonza
  • 他の有力企業および成長著しい企業
  • CMO事業部門を運営している主な生物医薬品メーカー
  • 本章のサマリー:2014〜2024年の主要企業

第7章 主要企業幹部のインタビュー

  • Fujifilm Diosynth Biotechnologies
  • Boehringer Ingelheim BioXcellence
  • KBI Biopharma
  • Vibalogics

第8章 本調査の結論

  • 2012〜2013年の市場
  • 2014〜2024年の市場展望

図表

目次

Outsourced biopharma production - new analysis announcing revenue prospects

What's the outlook for making biological active pharma ingredients (APIs) under contract? Visiongain's new report gives you predictions of those revenues from 2014. There you see financial data, also assessing trends, technologies, clients' needs, and opportunities.

That study gives you sales forecasts to 2024 at overall world market, submarket, and national level. Discover, then, what's happening for those production services - outsourcing and off-shoring for biomedicines. There you stay ahead in commercial knowledge.

So read on to explore that industry and find what its future revenues could be worth.

Sales forecasts and other information to help your research, analyses, and decisions

Our study shows you what the future holds there for pharma contract manufacturing organisations (CMOs). You see technological and commercial outlooks for producing medicinal components of biological drugs (biologics). Discover what's likely and possible.

Besides revenue forecasting to 2024, our new work shows you recent historical results, growth rates, and market shares. There you find original analysis. Explore trends and developments too. You get 68 tables, 54 charts, and four interviews with companies.

Gains through analysing those drug-making services - advantages for your work

So why miss information you need? Why struggle to find data? Instead let our analysis guide you through that outsourcing industry's present and future. Your search just got easier.

So our study could bring you quicker, easier decisions and progress. See how. Also you gain understanding to benefit your authority. Hear, then, where trends in that sector lead, exploring where the money lies.

Anyway the following sections show what you get in that new investigation.

Revenues for the world outsourced biological APIs market and submarkets

What're the secrets of that industry's progress? You find prediction of the overall world market for that biopharma production outsourcing. Our report also shows you individual revenue forecasting of three submarkets to 2024 at world level, with discussions:

  • Mammalian cell cultures
  • Microbial fermentations (culturing)
  • Other biotechnological systems for yielding medical products.

That work gives you feel for what stimulates and restrains that industry, also finding what its market could be worth. There you identify potentials and competition for those technologies, processes and applications.

Avoid falling behind, then, missing business or losing influence. Instead discover how you can benefit from better understanding of what's happening there from 2014.

You also find geographical revenue predictions.

National markets - what outlooks for service needs and CMOs serving biopharma?

Our work shows you individual revenue forecasts to 2024 for 14 national markets:

  • United States (US)
  • Japan
  • European leaders - Germany, France, the UK, Spain, Italy (EU5), and Switzerland
  • BRIC nations - Brazil, Russia, India, and China
  • Other emerging producers - Singapore and South Korea.

For the pharma service providers and their customers, many opportunities exist in developed and developing countries. Rising sales of novel biological drugs and biosimilars stimulate demands for outsourced producing of biologicals. Discover what's going on.

See there how you and your organisation could gain. You find needs and outlooks. Our work explains, also discussing issues affecting that outsourcing of bioproduction.

Developments, challenges, and opportunities affecting producers of biological APIs

Our study explains forces affecting that industry and market from 2013, including these:

  • Services in greatest demand for biopharma CMOs
  • Development and proliferation of cell lines and expression systems
  • Therapies in development (R&D) providing outsourcing opportunity for API makers
  • Overcoming challenges in making vaccines and other medicines
  • Revenues expected overall to 2024 for drug classes - see forecasts for monoclonal antibodies (mAbs), insulins, growth hormones, interferons, and vaccines.

And you also explore these aspects of the field:

  • Improving yields and efficiency in biopharmaceutical manufacture, including effects on downstream processing
  • Next-generation antibody development, including antibody-drug conjugates (ADCs)
  • Orphan drugs and personalised medicines, inc. producing APIs for clinical trials and scale-up
  • Single-use bioreactors for API manufacturers
  • Risks of overcapacity for biotechnological CMOs
  • Regulations affecting that drug making.

There you investigate political, economic, social, and technological questions, assessing outlooks for trade. You find what they mean for progress in that medical business.

So assess technological and commercial advances. You discover what the future holds.

Companies leading that industry and 2018 market value

What's possible for those pharma services? Our report predicts the world market for producing those therapeutic agents will reach $5.22bn in 2018, expanding to 2024.

Our analysis also shows you what organisations hold greatest potential. In particular, you explore activities of these companies:

  • Boehringer Ingelheim BioXcellence
  • Celltrion
  • DSM Biologics
  • Lonza
  • Samsung BioLogics.

You also assess capabilities and activities of other firms:

  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies
  • Gallus Biopharmaceuticals
  • AbbVie Contract Manufacturing
  • GSK Biopharmaceuticals
  • Sandoz.

You find 165 organisations mentioned. You also read interviews with four participants in the industry. Discover, then, what service providers do, say, and think, helping you stay ahead.

Ways Biotech API Manufacturing Services: World Industry and Market 2014-2024 helps

Through knowledge such as this, our new investigation benefits your work:

  • Revenues there to 2024 at world level, with forecasts for three main submarkets - assess prospects for investments, marketing, and sales
  • Forecasts to 2024 for 14 national markets in the Americas, Europe, and Asia -investigate developed and developing countries for commercial potentials
  • Outlooks for established and rising service providers - explore competitors' results, technology, capabilities, offerings, and strategies.

Information found nowhere else, helping your searches, analyses, and decisions

That new report provides independent analysis. There you gain competitive intelligence found only in our work, finding where money lies. So investigate progress and possibilities.

See there how you could help your research, analyses, and decisions. Also find how you could save time and get more recognition for insight, benefiting your influence.

Ordering now lets you discover predictions from 2014 - knowledge helping your work

Our new report shows you trends, opportunities, and revenue predictions to 2024 for contracted production of biopharmaceuticals. Try that study, then, seeing how you can gain. So avoid missing out - please order now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Contract Biotech API Manufacturing: World Market Review 2013
  • 1.2. Report Contents
    • 1.2.1. Benefits of this Report
  • 1.3. Methods of the Study
    • 1.3.1. Who is this Report for?
    • 1.3.2. Defining the Contract Biotech API Manufacturing Market
  • 1.4. An Introduction to Biotech API Manufacturing
    • 1.4.1. Producing Biological Drugs: An Introduction to the Manufacturing Process
      • 1.4.1.1. Cell Line Development and Proliferation
    • 1.4.2. There are Challenges in Manufacturing Biotech APIs
    • 1.4.3. Outsourcing Biotech API Manufacturing
    • 1.4.4. Future Trends in Biotech API Manufacturing

2. Contract Biotech API Manufacturing: World Market Outlook and Forecast 2014-2024

  • 2.1. Demand for Outsourced Biotech API Manufacturing 2012-2013
    • 2.1.1. What Services are in Greatest Demand from Biopharma CMOs?
  • 2.2. The Outsourced Biotech API Manufacturing Market 2014-2024
    • 2.2.1. Strong Growth for the Biological Drugs Market 2014-2024
    • 2.2.2. Outsourced Biotech API Manufacturing Market Forecast 2014-2024
    • 2.2.3. What Will Drive Market Growth to 2024?
    • 2.2.4. In-House Expertise and Manufacturing Will Restrain Growth
    • 2.2.5. Contract Biotech API Manufacturing: Submarket Shares 2014-2024
  • 2.3. The Mammalian Cell Culture Submarket 2014-2024
    • 2.3.1. Mammalian Cell Culture: Submarket Forecast 2014-2024
    • 2.3.2. Antibody Drug Development Will Drive Submarket Growth to 2024
  • 2.4. The Microbial Fermentation Submarket 2014-2024
    • 2.4.1. Microbial Fermentation: Submarket Forecast 2014-2024
    • 2.4.2. Submarket Drivers and Restraints 2014-2024
  • 2.5. Chapter Summary: Strong Market Growth Forecast 2012-2024

3. Leading National Markets for Contract Biotech API Manufacturing 2014-2024

  • 3.1. The US and Europe Dominate Contract Biopharmaceutical Manufacturing 2012-2013
    • 3.1.1. Growth for Leading National Submarkets 2014-2024
    • 3.1.2. How Will National Submarket Shares Change to 2024?
  • 3.2. Contract Biotech API Manufacturing in Europe 2014-2024
    • 3.2.1. Biotech Research Is Growing Strongly in Europe
    • 3.2.2. The European Submarket: Revenue Forecast 2014-2024
    • 3.2.3. Leading EU National Submarkets 2014-2024
    • 3.2.4. Germany Is Europe's Biopharmaceutical Production Leader
    • 3.2.5. The UK Contract Biotech API Manufacturing Submarket 2014-2024
      • 3.2.5.1. High Demand Expected in the UK 2014-2024
    • 3.2.6. France: Contract Biotech API Submarket Forecast 2014-2024
    • 3.2.7. Switzerland Is a Leading Biotech R&D Destination
    • 3.2.8. Spain: Submarket Forecast 2014-2024
    • 3.2.9. Italy: Traditional Strength in Small Molecule APIs
  • 3.3. The US: The Largest National Submarket for Biotech API Manufacturing
    • 3.3.1. Expanding Clinical Capacity to Drive US Submarket Growth 2014-2024
  • 3.4. Japan: A Relatively New Contract Biotech Manufacturing Submarket
    • 3.4.1. Japanese Contract Biotech API Manufacturing Submarket Forecast 2014-2024
  • 3.5. Contract Biotech API Manufacturing in Emerging Markets 2014-2024
    • 3.5.1. Biologics Markets Are Small in Emerging Nations in 2013
    • 3.5.2. Increased Biosimilar and Biological Drug Development 2014-2024
    • 3.5.3. CMOs Are Investing in China
      • 3.5.3.1. Chinese Contract Biotech API Manufacturing Submarket Forecast 2014-2024
    • 3.5.4. Contract Biotech API Manufacturing in India 2014-2024
    • 3.5.5. There Are Two Large Biotech CMOs in South Korea 2013
      • 3.5.5.1. South Korea: Submarket Forecast 2014-2024
    • 3.5.6. Increased Investment in Singapore 2014-2024
    • 3.5.7. Governments in Brazil and Russia Are Promoting Domestic Biotech Development
      • 3.5.7.1. Russia: Submarket Forecast 2014-2024
      • 3.5.7.2. Brazil: Submarket Forecast 2014-2024
  • 3.6. Chapter Summary: Outlook for Leading National Submarkets 2014-2024

4. Biotech API Manufacturing: Outlook for Leading Biological Drug Sectors 2014-2024

  • 4.1. Antibody Therapies: The Largest Biological Drug Sector 2014-2024
    • 4.1.1. Monoclonal Antibody Manufacturing 2013
      • 4.1.1.1. CHO Cell Lines Dominate in 2013
      • 4.1.1.2. Future Developments in Antibody Expression Systems
    • 4.1.2. Outsourced Manufacturing for Antibody APIs
      • 4.1.2.1. There Are Many Clinical Manufacturing Opportunities
    • 4.1.3. Next-Generation Antibody Therapies Offer New Challenges for CMOs
  • 4.2. The Outlook for Insulin Therapies 2014-2024
    • 4.2.1. Manufacturing Trends for Insulin Analogues 2014-2024
    • 4.2.2. Leading Insulin Analogues Are Produced In-House
    • 4.2.3. Development Trends in the Insulin Market to 2024
  • 4.3. Growth Hormone API Manufacturing 2014-2024
    • 4.3.1. Outlook for the Growth Hormone Market to 2024
    • 4.3.2. Long-Acting Therapies in Development May Provide Outsourcing Opportunities
  • 4.4. The Interferon Therapy Market 2014-2024
    • 4.4.1. Multiple Expression Systems Used for Leading Interferons
    • 4.4.2. Contract Manufacturing for Commercial and Clinical Interferon Therapies
    • 4.4.3. Is There Demand for Long-Acting Interferon Beta Therapies?
  • 4.5. Vaccine Manufacturing: An Alternative Market Opportunity for CMOs
    • 4.5.1. The Vaccines Market: Outlook and Forecast 2014-2024
    • 4.5.2. Contract Manufacturing for Vaccines 2014-2024
    • 4.5.3. Challenges in Manufacturing Vaccines
  • 4.6. Chapter Summary: Outsourcing for Key Biological Products 2014-2024

5. Biotech API Manufacturing: Industry Trends 2014-2024

  • 5.1. Contract Biotech API Manufacturing: Strengths and Weaknesses 2012-2013
    • 5.1.1. Manufacturing Biological Drugs is Complex
  • 5.2. Contract Biotech API Manufacturing: Opportunities and Threats 2014-2024
  • 5.3. Contract Biotech API Manufacturing Market: STEP Analysis 2014-2024
    • 5.3.1. Social Factors: Rising Demand for Biological Medicines
    • 5.3.2. Technological Developments Will Drive More-Efficient Manufacturing
      • 5.3.2.1. Improving Yields and Efficiency in Biopharmaceutical Manufacturing
      • 5.3.2.2. The Impact of Higher Yields on Downstream Processing
    • 5.3.3. Economic Pressures: Strains on Healthcare Budgets
    • 5.3.4. Political Issues: Regulatory Developments to Affect Drug Manufacturing
  • 5.4. Trends in Biological Drug Development 2014-2024
    • 5.4.1. Biosimilars as an Opportunity for CMOs
    • 5.4.2. Next-Generation Antibody Development
    • 5.4.3. Orphan Drugs and Personalised Medicine: Smaller Batches and Greater Flexibility Will be Required
    • 5.4.4. Manufacturing APIs for Clinical Trials and Scale-Up
  • 5.5. Outlook for Single-Use Technologies in Biotech API Manufacturing 2014-2024
    • 5.5.1. The Benefits of Single-Use for Biotech API Manufacturing
    • 5.5.2. What Limitations Exist for Single-Use Technologies in 2013?
    • 5.5.3. Single-Use in Downstream Processing
    • 5.5.4. CMOs Are Rapidly Adopting Single-Use Systems
    • 5.5.5. Future Directions in Single-Use Technologies for Biotech API Manufacturing
  • 5.6. Outsourcing Trends for Biotech API Manufacturing 2014-2024
    • 5.6.1. Biopharma Companies Continue to Invest in In-House Facilities
    • 5.6.2. Offshoring Biotech API Manufacturing to Emerging Markets: Not a Trend for this Decade?
    • 5.6.3. Is There a Risk of Overcapacity for the Biotech CMO Industry?
  • 5.7. New Production Platforms for Biotech API Manufacturing to 2024
    • 5.7.1. Plant Made Pharmaceuticals (PMPs)
    • 5.7.2. Transgenic Systems
  • 5.8. Chapter Summary: Industry Trends for Contract Biotech API Manufacturing to 2024

6. Leading CMOs Manufacturing Biotech APIs 2013

  • 6.1. Four Companies Lead the Market 2013
    • 6.1.1. Many CMOs Offer Small-Scale Biopharmaceutical Manufacturing
    • 6.1.2. Barriers to Market Entry 2014-2024
      • 6.1.2.1. Biologics Manufacturing Facilities Are Costly to Set Up
  • 6.2. Boehringer Ingelheim BioXcellence
    • 6.2.1. Investing in New Services 2012-2013
    • 6.2.2. Expanding Manufacturing into Asia
  • 6.3. Celltrion: Market-Leading Capacity in Asia
    • 6.3.1. Celltrion Aims to Become a Leading Biopharmaceutical Developer
  • 6.4. DSM Biologics
    • 6.4.1. DSM Invests in Single-Use Technologies
  • 6.5. Lonza
    • 6.5.1. Lonza is a Leader in Cell Culture Scale
    • 6.5.2. Steady Increase in Demand, 2011-2013
    • 6.5.3. Investing in Next-Generation Biologics Production
  • 6.6. Other Leading and Fast-Growing Market Players 2013
    • 6.6.1. Samsung BioLogics
    • 6.6.2. Cytovance Biologics
    • 6.6.3. Fujifilm Diosynth Biotechnologies
      • 6.6.3.1. Facility and Service Expansion 2012-2013
    • 6.6.4. Gallus Biopharmaceuticals
      • 6.6.4.1. Gallus Acquires Laureate Biopharma, Doubling Capacity in the US
  • 6.7. Leading Biopharmaceutical Companies Operate CMO Divisions
    • 6.7.1. AbbVie Contract Manufacturing
    • 6.7.2. GSK Biopharmaceuticals
    • 6.7.3. Sandoz
  • 6.8. Chapter Summary: Leading Companies 2014-2024

7. Research Interviews

  • 7.1. Dr Stephen Taylor, SVP and Commercial Director Fujifilm Diosynth Biotechnologies
    • 7.1.1. Biotech API Manufacturing as an Opportunity for CMOs
    • 7.1.2. Single-Use Technologies and Biopharmaceutical Manufacturing
    • 7.1.3. Major Technology Trends for Biologics
    • 7.1.4. Emerging Markets in the Biotech API Manufacturing Market
  • 7.2. Company Insight: Boehringer Ingelheim BioXcellence
    • 7.2.1. Recent Demand for Contract Biomanufacturing
      • 7.2.1.1. Future Demand for Services
    • 7.2.2. Drug Development Trends Affecting Biopharmaceutical CMOs
    • 7.2.3. Commercial Drivers and Restraints
  • 7.3. Dr Abhinav Shukla, Vice President, Process Development and Manufacturing, KBI Biopharma
    • 7.3.1. KBI Biopharma
    • 7.3.2. Single-Use Technologies in Biopharma Manufacturing
    • 7.3.3. Demands for Biopharma Manufacturing Services
    • 7.3.4. Outlook for the US Contract Manufacturing Market
  • 7.4. Dr Stefan Beyer, CEO, Vibalogics
    • 7.4.1. Vibalogics: Company Overview
    • 7.4.2. Outsourcing Vaccine Manufacturing
    • 7.4.3. Challenges in Vaccine Manufacturing
    • 7.4.4. Developments in Technology and Vaccine R&D to Affect CMOs

8. Conclusions to Our Study

  • 8.1. The Contract Biotech API Manufacturing Market 2012-2013
    • 8.1.1. Mammalian Cell Culture Dominates Outsourced Biotech API Manufacturing in 2013
    • 8.1.2. The US and Europe Supplied 80% of the World's Outsourced Biotech APIs in 2012
  • 8.2. Outlook for the Biotech API Manufacturing Market 2014-2024
    • 8.2.1. New Technology Will Stimulate Market Expansion
    • 8.2.2. Growth in the Market 2014-2024
    • 8.2.3. The Future of Biotech API Supply in Emerging National Markets

List of Tables

  • Table 1.1: Currency Exchange Rates
  • Table 2.1: Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2012
  • Table 2.2: Top Ten Bestselling Biologics: Market Sectors and Revenues ($bn), 2012
  • Table 2.3: Contract Biotech API Manufacturing Market: Revenues ($bn) by Sector, 2012-2013
  • Table 2.4: Contract Biotech API Manufacturing Market: Overall Market and Revenue Forecasts ($bn) by Sector, 2012-2024
  • Table 2.5: Contract Biotech API Manufacturing Market: Submarket Shares (%), 2012-2024
  • Table 2.6: Mammalian Cell Culture Submarket: Revenue Forecast ($bn), 2012-2024
  • Table 2.7: Microbial Fermentation Submarket: Revenue Forecast ($bn), 2012-2024
  • Table 3.1: Contract Biotech API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2012
  • Table 3.2: Contract Biotech API Manufacturing Market: Leading Regional and National Submarket Revenue Forecasts ($bn), 2012-2024
  • Table 3.3: Contract Biotech API Manufacturing Market: National Submarket Shares (%), 2012-2024
  • Table 3.4: Leading European Contract Biotech API Manufacturing Submarket: Leading National Submarket Revenue Forecasts ($bn), 2012-2024
  • Table 3.5: European Contract Biotech API Manufacturing Submarket: Revenues ($bn) and Submarket Shares (%) by Leading Country, 2012
  • Table 3.6: German Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.7: UK Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.8: French Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.9: Swiss Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.10: Spanish Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.11: Italian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.12: US Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.13: Japanese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.14: Contract Biotech API Manufacturing Market: Emerging National Submarket Revenue Forecasts ($bn), 2012-2024
  • Table 3.15: Biologics Market: Emerging Submarket Revenues ($bn) and Market Shares (%), 2012
  • Table 3.16: Chinese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.17: Indian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.18: South Korean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.19: Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2013
  • Table 3.20: Singaporean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.21: Russian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 3.22: Brazilian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Table 4.1: Lonza: New Biological Drug Sector Manufacturing Agreements, 2012-2013
  • Table 4.2: US Biologics Clinical Pipeline by Sector, 2013
  • Table 4.3: Monoclonal Antibody Market: Revenue Forecast ($bn), 2012-2024
  • Table 4.4: Monoclonal Antibody Types and Sources
  • Table 4.5: Blockbuster Antibody Therapies: Antibody Types and Sources
  • Table 4.6: Contract Manufacturers for Leading Antibody Therapies, 2013
  • Table 4.7: Clinical Contract Manufacturing Agreements for Antibody Therapies, 2013
  • Table 4.8: Next-Generation Antibody Therapy Pipeline by Drug Type, 2013
  • Table 4.9: Insulin Therapies Market: Revenue Forecast ($bn), 2012-2024
  • Table 4.10: Expression Systems for Leading Insulin Analogues
  • Table 4.11: Growth Hormone Market by Drug: Revenues ($bn) and Market Share (%), 2012
  • Table 4.12: Growth Hormones Market: Revenue Forecast ($bn), 2012-2024
  • Table 4.13: Selected Long-Acting Growth Hormones in Development, 2013
  • Table 4.14: Interferon Therapies Market: Revenue Forecast ($bn), 2012-2024
  • Table 4.15: Interferon API Manufacturers in the EU, 2013
  • Table 4.16: Vaccines Market: Revenue Forecast ($bn), 2012-2024
  • Table 4.17: Vaccine Contract Manufacturing Market: Revenue Forecast ($bn), 2012-2024
  • Table 5.1: Contract Biotech API Manufacturing Market: Strengths and Weaknesses, 2012-2013
  • Table 5.2: Contract Biotech API Manufacturing Market: Opportunities and Threats, 2014-2024
  • Table 5.3: Contract Biotech API Manufacturing Market: STEP Analysis, 2014-2024
  • Table 5.4: EU-Approved Biosimilars: Marketers and Manufacturers, 2013
  • Table 5.5: Approved Next-Generation Antibody Therapies, 2013
  • Table 5.6: Selected Single-Use Bioreactors Available Commercially, 2013
  • Table 6.1: Leading Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2013
  • Table 6.2: Selected Other Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2013
  • Table 6.3: Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2013
  • Table 6.4: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2012
  • Table 6.5: Celltrion: Revenue ($bn), 2007-2012
  • Table 6.6: Celltrion: Recent Biosimilar Licensing Agreements
  • Table 6.7: DSM Biologics: Manufacturing Capacity, 2013
  • Table 6.8: DSM: Pharmaceutical Contract Manufacturing: Revenue ($bn), H1 2012-2013
  • Table 6.9: Lonza: Biotech API Manufacturing Capacity, 2013
  • Table 6.10: Lonza: Revenue ($bn), 2008-2012
  • Table 6.11: Cytovance Biologics: Revenue ($m) and Employees, 2008 and 2013
  • Table 6.12: Fujifilm Diosynth Biotechnologies: Commercial Manufacturing Agreements, 2013
  • Table 6.13: Sandoz: Biosimilars Revenue ($m), 2011-2012
  • Table 8.1: Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) and Market Shares (%) by Sector, 2012, 2015, 2018, 2021 and 2024
  • Table 8.2: Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) and Market Shares (%) by Region, 2012, 2015, 2018, 2021 and 2024

List of Figures

  • Figure 1.1: Key Steps in the Biological Drug Manufacturing Process
  • Figure 1.2: Contract Biotech API Manufacturing: Major Market Trends, 2014-2024
  • Figure 2.1: Contract API Manufacturing: Market Shares by Sector (%), 2012
  • Figure 2.2: Contract Biotech API Manufacturing Market: Revenues by Sector ($bn), 2012-2013
  • Figure 2.3: World Biologics Market: Revenue Forecast ($bn), 2012-2024
  • Figure 2.4: Contract Biotech API Manufacturing Market: Revenue Forecast ($bn), 2012-2024
  • Figure 2.5: Contract Biotech API Manufacturing: Market Drivers, 2014-2024
  • Figure 2.6: Contract Biotech API Manufacturing: Market Restraints, 2014-2024
  • Figure 2.7: Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2018
  • Figure 2.8: Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2024
  • Figure 2.9: Mammalian Cell Culture Submarket: Revenue Forecast ($bn), 2012-2024
  • Figure 2.10: Mammalian Cell Culture Submarket: Drivers and Restraints, 2014-2024
  • Figure 2.11: Microbial Fermentation Submarket: Revenue Forecast ($bn), 2012-2024
  • Figure 2.12: Microbial Fermentation Submarket: Drivers and Restraints, 2014-2024
  • Figure 3.1: Contract Biotech API Manufacturing: Market Shares by Region (%), 2012
  • Figure 3.2: Contract Biotech API Manufacturing: Market Shares by Region (%), 2018
  • Figure 3.3: Contract Biotech API Manufacturing: Market Shares by Region (%), 2024
  • Figure 3.4: European Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.5: European Contract Biotech API Manufacturing Submarket: National Submarket Shares (%), 2012
  • Figure 3.6: German Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.7: UK Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.8: French Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.9: Swiss Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.10: Spanish Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.11: Italian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.12: US Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.13: Japanese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.14: Contract Biotech API Manufacturing Market: Emerging National Submarket Revenue Forecasts ($bn), 2012 and 2024
  • Figure 3.15: Biologics Market: Emerging Submarket Shares (%), 2012
  • Figure 3.16: Chinese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.17: Indian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.18: South Korean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.19: Singaporean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.20: Russian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 3.21: Brazilian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024
  • Figure 4.1: US Biologics Clinical R&D Pipeline by Sector, 2013
  • Figure 4.2: Monoclonal Antibody Market: Revenue Forecast ($bn), 2012-2024
  • Figure 4.3: Insulin Therapies Market: Revenue Forecast ($bn), 2012-2024
  • Figure 4.4: Growth Hormones Market: Revenue Forecast ($bn), 2012-2024
  • Figure 4.5: Interferon Therapies Market: Revenue Forecast ($bn), 2012-2024
  • Figure 4.6: Vaccines Market: Revenue Forecast ($bn), 2012-2024
  • Figure 4.7: Vaccine Contract Manufacturing Market: Revenue Forecast ($bn), 2012-2024
  • Figure 5.1: Biosimilars Market: Revenue Forecast ($bn), 2012, 2018 and 2024
  • Figure 5.2: Cost-Savings for Single-Use Bioreactors
  • Figure 6.1: Leading Biotech API CMOs: Mammalian Cell Culture Manufacturing Scale, 2013
  • Figure 6.2: Leading Biotech API CMOs: Microbial Fermentation Manufacturing Scale, 2013
  • Figure 6.3: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2012
  • Figure 6.4: Celltrion: Revenue ($bn), 2007-2012
  • Figure 6.5: DSM: Pharmaceutical Contract Manufacturing: Revenue ($bn), H1 2012-2013
  • Figure 6.6: Lonza: Revenue ($bn), 2008-2012
  • Figure 6.7: Cytovance Biologics: Revenue ($m), 2008 and 2013
  • Figure 6.8: Sandoz: Biosimilars Revenue ($m), 2011-2012
  • Figure 8.1: Contract Biotech API Manufacturing Market: Revenue Forecast ($bn) by Sector, 2012, 2015, 2018, 2021 and 2024
  • Figure 8.2: Contract Biotech API Manufacturing Market: Revenue Forecast ($bn) by Region, 2012, 2015, 2018, 2021 and 2024

Companies Listed

  • 3P Biopharmaceuticals
  • A5 Laboratories
  • AbbVie
  • AbbVie Contract Manufacturing (part of AbbVie)
  • A-Bio Pharma
  • Actavis
  • Adocia
  • Alexion Pharmaceuticals
  • Althea Technologies
  • Altus Pharmaceuticals
  • American Diabetes Association
  • Amgen
  • Apexigen
  • Association of the British Pharmaceutical Industry (ABPI)
  • AstraZeneca
  • Athera Biotechnologies
  • AutekBio
  • Avalanche Biotechnologies
  • Bachem
  • BaroFold
  • Baxter International
  • Bayer
  • Biocad
  • Bioceuticals Arzneimittel (part of Stada)
  • Biocon
  • Biogen Idec
  • Bionomics
  • Bioprocessing Technology Institute (BTI)
  • Biosidus
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)
  • Bristol-Myers Squibb
  • Catalent Pharma Solutions
  • Celladon
  • Celltrion
  • Centocor Ortho Biotech (now Janssen Biotech, part of J&J)
  • CinnaGen
  • CMC Biologics
  • Cook Pharmica
  • Cornerstone Therapeutics
  • Critical Pharmaceuticals
  • Crucell (part of J&J)
  • CT Arzneimittel (part of Teva)
  • Cytogen (part of EUSA Pharma)
  • Cytovance Biologics
  • Dendreon
  • DSM Biologics (part of Royal DSM)
  • Dyax
  • Eclipse Therapeutics (part of Bionomics)
  • Eden Biodesign (part of Actavis)
  • Egis Pharmaceuticals
  • Eli Lilly
  • Elona Biotechnologies (part of Zimmerman Biotechnologies)
  • EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
  • Emcure Pharmaceuticals
  • European Medicines Agency (EMA)
  • EUSA Pharma (part of Jazz Pharmaceuticals)
  • Food and Drug Administration (FDA) [US]
  • Fountain Biopharma
  • Fresenius
  • Fujifilm
  • Fujifilm Diosynth Biotechnologies
  • Gallus Biopharmaceuticals
  • GE Healthcare
  • Genentech (part of Roche)
  • Genmab
  • Genzyme (part of Sanofi)
  • GlyTech
  • GSK
  • GSK Biopharmaceuticals (part of GSK)
  • GTC Biotherapeutics
  • Hexal Arzneimittel (part of Novartis)
  • Hikma Pharmaceuticals
  • Hospira
  • Hospira One2One (part of Hospira)
  • Human Genome Sciences (part of GSK)
  • Hyclone (part of Thermo Fisher Scientific)
  • iBio
  • IHI Corporation
  • immatics
  • Immune Pharmaceuticals
  • Inno Biologics
  • Intellect Neurosciences
  • J&J
  • KBI Biopharma
  • Kemwell Biopharma
  • kSep Systems (part of KBI Biopharma)
  • Kyowa Hakko Kirin
  • Laureate Biopharma (part of Gallus Biopharmaceuticals0
  • Lek Pharmaceuticals (Sandoz)
  • LG Life Sciences
  • Lonza
  • Medical Research Council (MRC) [UK]
  • Medice
  • MedImmune (part of AstraZeneca)
  • Merck & Co.
  • Merck Serono
  • Merckle (part of Teva)
  • Ministry of Health [Brazil]
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]
  • Nippon Kayaku
  • Norbitec
  • Novartis
  • Novo Nordisk
  • Nuron Biotech
  • OncoMed Pharmaceuticals
  • Open Monoclonal Technology (OMT)
  • PanGen Biotech
  • Pfizer
  • Pfizer CentreSource (part of Pfizer)
  • Pharming
  • Pharmstandard
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • PHW Group
  • Pierre Guerin
  • Piramal Healthcare
  • PlantForm
  • PolyTherics
  • ProBioGen
  • Prolor Biotech
  • Protalix BioTherapeutics
  • Purdue Pharma
  • Quintiles
  • ratiopharm (part of Teva)
  • Recepta Biopharma
  • Reliance Life Sciences
  • Rentschler Biotechnologie
  • Ridgemont Equity Partners
  • Roche
  • Royal DSM
  • SAFC (part of Sigma-Aldrich)
  • Samsung
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz (part of Novartis)
  • Sanofi
  • Sartorius Stedim Biotech
  • Schering-Plough (part of Merck & Co.)
  • Seattle Genetics
  • ShanghaiTech University
  • SICOR Biotech (part of Teva)
  • Stada Arzneimittel
  • SynCo Bio Partners
  • Synpromics
  • Synthon
  • TaiMed Biologics
  • Technology Strategy Board (TSB) [UK]
  • Teva Pharmaceutical Industries
  • Therapure Biopharma
  • Thermo Fisher Scientific
  • ThromboGenics
  • Toyobo Biologics
  • Tufts Center for the Study of Drug Development (CSDD)
  • UCB
  • UMN Pharma
  • Unigen (part of UMN Pharma)
  • University of Arkansas
  • Versartis
  • Vibalogics (part of PHW Group)
  • Vida Pharma
  • Wacker Biotech
  • Wave Biotech (part of GE Healthcare)
  • World Health Organization (WHO)
  • WuXi PharmaTech
  • Xcellerex
  • Zhangjiang Biotech and Pharmaceutical Base Development (ZJ Base)
  • Zimmerman Biotechnologies
Back to Top